Midodrine During Recovery From Septic Shock

A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02771158

Enrollment

Registered

2016-05-12

Start date

2017-08-31

Completion date

2017-11-01

Last updated

2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension, Sepsis, Shock, Septic

Keywords

critical care, shock, septic, sepsis, hypotension, midodrine

Brief summary

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.

Interventions

DRUGMidodrine

midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure

DRUGplacebo

placebo will be administered to double blind the study

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* admitted to intensive care unit * diagnosis of septic shock on intravenous vasopressors * stable/decreasing doses of intravenous vasopressors * stable/improving organ function

Exclusion criteria

* allergy to midodrine * multiple intravenous vasopressors * increasing intravenous vasopressor requirements * worsening organ dysfunction * severe bradycardia

Design outcomes

Primary

Measure	Time frame
duration of intravenous vasopressors	from enrollment until discontinuation of intravenous vasopressors, expected to be 3-5 days

Secondary

Measure	Time frame	Description
intensive care unit length of stay	from enrollment until eligible for discharge from intensive care unit, expected to be 4-7 days	—
re-institution of intravenous vasopressor	from enrollment until hospital discharge, expected to be up to 30 days	—
hospital length of stay	from enrollment until hospital discharge, expected to be up to 30 days	—
mortality	from enrollment until hospital discharge, expected to be up to 30 days	—
midodrine side effects requiring discontinuation	from enrollment until hospital discharge, expected to be up to 30 days	including supine hypertension and bradycardia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026